Trials / Available
AvailableNCT05544032
Expanded Access of Axatilimab to Treat a Single Patient With Chronic Graft Versus Host Disease (GVHD)
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Incyte Corporation · Industry
- Sex
- —
- Age
- —
- Healthy volunteers
- —
Summary
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee and Single Patient IND approval.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | axatilimab | Treatment with axatilimab includes receiving intravenous (IV) doses of axatilimab every 2 weeks |
Timeline
- First posted
- 2022-09-16
- Last updated
- 2025-10-08
Source: ClinicalTrials.gov record NCT05544032. Inclusion in this directory is not an endorsement.